Intravitreal Injection of Ranibizumab Using A pro Re Nata Regimen for Age-Related Macular Degeneration and Vision-Related Quality of Life

Clinical Ophthalmology - New Zealand
doi 10.2147/opth.s68293
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Informa UK Limited

Related search

Outcomes When Switching From a Pro Re Nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration

Ophthalmologica
MedicineOphthalmologySensory Systems
2016English

One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Journal of Ophthalmology
Ophthalmology
2019English

Early Changes in Retinal Thickness When Using Intravitreal Ranibizumab for Age‐related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Five-Year Outcomes of a Personalized Pro Re Nata Treatment Regimen With Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Choroidal Blood Flow After the First Intravitreal Ranibizumab Injection in Neovascular Age-Related Macular Degeneration Patients

Acta Ophthalmologica
MedicineOphthalmology
2018English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2016English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Functional and Anatomical Outcome of Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab Following an Exit Strategy Regimen

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2014English

Age-Related Macular Degeneration and Quality of Life in Latinos

JAMA Ophthalmology
Ophthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy